U.S. markets close in 5 hours 41 minutes
  • S&P 500

    3,755.89
    -27.39 (-0.72%)
     
  • Dow 30

    30,041.75
    -232.12 (-0.77%)
     
  • Nasdaq

    11,079.65
    -68.99 (-0.62%)
     
  • Russell 2000

    1,759.31
    -3.39 (-0.19%)
     
  • Crude Oil

    88.06
    +0.30 (+0.34%)
     
  • Gold

    1,720.20
    -0.60 (-0.03%)
     
  • Silver

    20.49
    -0.06 (-0.29%)
     
  • EUR/USD

    0.9837
    -0.0048 (-0.48%)
     
  • 10-Yr Bond

    3.8160
    +0.0570 (+1.52%)
     
  • GBP/USD

    1.1221
    -0.0100 (-0.89%)
     
  • USD/JPY

    144.8480
    +0.2380 (+0.16%)
     
  • BTC-USD

    20,006.52
    +146.15 (+0.74%)
     
  • CMC Crypto 200

    454.51
    -8.61 (-1.86%)
     
  • FTSE 100

    6,973.14
    -79.48 (-1.13%)
     
  • Nikkei 225

    27,311.30
    +190.77 (+0.70%)
     

First-on-Podium Data from 21 Vascular Interventional Clinical Trials to Be Presented at The VEINS and VIVA 2022

·4 min read

PALM SPRINGS, Calif., Sept. 1, 2022 /PRNewswire/ -- Leading physicians and researchers will present results from 21 clinical trials from Monday, October 31, to Wednesday, November 2, at the annual VIVA and The VEINS conferences at Wynn Las Vegas.

The VIVA Foundation logo - all rights reserved
The VIVA Foundation logo - all rights reserved

VIVA (Vascular InterVentional Advances) is a vascular education symposium that emphasizes innovation and multidisciplinary learning. The 2022 conference will mark VIVA's 20th anniversary as a premier educational event for endovascular specialists.

The VEINS (Venous Endovascular INterventional Strategies) is a comprehensive education symposium focused on the diagnosis, intervention, and management of venous disorders.

VIVA and The VEINS bring together a global, multispecialty faculty to present a variety of talks and live case presentations from clinical centers around the world. Attendees for both events include an audience of interventional cardiologists, interventional radiologists, vascular surgeons, and endovascular medicine specialists.

Media outlets are invited to attend the data presentations in person. The presentations will also be available to all VIVA attendees and invited press through the Virtual VIVA app. Any members of the press planning to attend should contact press@vivaphysicians.org.

To view the full schedule for both conferences, please visit https://viva-foundation.org/agenda

Clinical trial results to be released (in alphabetical order):

The VEINS
ABRE Study: Clinical Outcomes by Initial Clinical Presentation Through 36 Months
Stephen A. Black, MD

Decreased ICU Cost for Iliofemoral DVT Patients Treated With Thrombectomy
John Filtes, MD

First-in-Human Study Results With Amplifi™ Vein Dilation System Treatment
Surendra Shenoy, MD, PhD

Improvement in Clinical and Echo Parameters After Computer-Aided Mechanical Aspiration Thrombectomy for Treatment of Acute Pulmonary Embolism
Elias Iliadis, MD

In-Hospital and 30-day Outcomes from the Fully-Enrolled, Multicenter, Prospective CLOUT Registry
David Dexter, MD

Propensity-Score Matched Analysis of Early Clinical Outcomes From the CLOUT and ATTRACT Studies
Steven Abramowitz, MD

VIVA
3-Year results of the GORE® VIABAHN® Stent-Graph in the Superficial Femoral Artery for In-Stent Restenosis
Peter Soukas, MD

12-Month Results from a Prospective Study of the Rotarex Atherectomy and Thrombectomy Catheter System
Michael Lichtenberg, MD

36-Month Outcomes for the BioMimics Stent in Longer Lesions: A Subgroup Analysis of the MIMICS-3D EU Registry
Michael Lichtenberg, MD

A Patient-Level, Propensity-Adjusted Comparison of Drug-Coated Balloons vs Bare Metal Stents in Femoropopliteal Lesions: 3-Year Results in Prospective, Multicenter Studies
Mehdi Shishehbor, DO, MPH, PhD

A Registry-Based Study of Paclitaxel Drug-Coated Balloon Angioplasty for the Treatment of In-Stent Restenosis of the Femoral-Popliteal Artery
Daniel Bertges, MD

Cross-Seal™ IDE Trial: Prospective, Multi-Center, Single Arm Study of the Cross-Seal™ Suture-Mediated Vascular Closure Device System
Prakash Krishnan, MD

ELEGANCE: Increasing Diversity in Peripheral Artery Disease Trials
Maureen Kohi, MD

Intermediate Term (24-Month) Results of the TRANSCEND Study Comparing a Next-Generation Paclitaxel Drug-Coated Balloon (SurVeil DCB) to IN.PACT Admiral DCB in the Treatment of Femoropopliteal Artery Disease
Kenneth Rosenfield, MD

Intravascular Lithotripsy for the Treatment of Peripheral Artery Calcification: Results from the Disrupt PAD III Observational Study
Ehrin Armstrong, MD

Percutaneous Bypass for Treatment of Femoropopliteal Disease: 1-Year Outcomes of the DETOUR-2 Study
Sean Lyden, MD

Periprocedural and Patient-Reported Quality of Life Outcomes After Computer-Aided Mechanical Aspiration Thrombectomy for the Treatment of Acute Pulmonary Embolism: Interim Analysis of the STRIKE-PE Study
Ido Weinberg, MD

Revascularization Therapy for Femoropopliteal Disease With a Novel Intra-Arterial Stent Graft: 12-Month Results of the TORUS-2 Study
Ehrin Armstrong, MD

Safety and Performance of the Indigo Aspiration System for the Treatment of Lower Extremity Acute Limb Ischemia: Interim Analysis of the STRIDE Study
Thomas Maldonado, MD

The AFX2 Anatomically Fixated Endograft Has Similar Outcomes to Commercially Available Proximally Fixated Endografts: 5-Year Results of the LEOPARD Trial
Christopher Kwolek, MD, MBA

Utility of Sirolimus Drug Eluting Balloons in the Treatment of Complex Below-the-Knee Atherosclerotic Disease in Patients With Chronic Limb-Threatening Ischemia – 24-Month Results From the PRESTIGE Study
Tjun Tang, MD

About the VIVA Foundation

The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, strives to be the premier educator in the field. Our team of specialists in vascular medicine, interventional cardiology, interventional radiology, and vascular surgery is driven by the passion to advance the field and improve patient outcomes. Educational events presented by the VIVA Foundation have a distinct spirit of collegiality attained by synergizing collective talents to promote awareness and innovative therapeutic options for vascular disease worldwide.

To learn more about the VIVA Foundation, visit https://viva-foundation.org/.

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/first-on-podium-data-from-21-vascular-interventional-clinical-trials-to-be-presented-at-the-veins-and-viva-2022-301616769.html

SOURCE The VIVA Foundation